Advertisement
"After multi-year due diligence on 2 companies in the field of I.V.Robotics, the doubts we had on this exciting new technology [due to RIVA'spublicly announced multi-year delays in bringing their robot to firsthospital's use], and the large capital investment required to automate ourI.V. Centers, these 3 factors demanded that we witnessed the real results ofthese IV Robots with actual hospital visits, rather than simply rely onvendors' stated vision or promises. I visited RIVA's Children's Hospital ofOrange County and Health Robotics' University of Colorado and Umberto IUniversity Hospitals. After seeing real patient utilization, we quicklydecided to select Health Robotics due to their unique ability to compoundboth chemotherapy and non-hazardous I.V. Admixtures, much lower total cost ofownership, and finally the fact that in my opinion, Health Robotics'technology is two to three years ahead of RIVA's", stated Dr ViswanathanMukaya, CEO of Dr M Group.
Advertisement
Since Dr M Group wished to deploy both Cytocare and i.v.STATION on a"pay-per-dose" basis rather than with typical upfront capital investment,this business model, arguably more suited to the South East Asia healthcaremarket, demanded an adjustment of Health Robotics' customary global indirectsales-channel strategy. Without losing Health Robotics' stated philosophy ofmulti-year recurring revenue streams and after Dr M Group's selection ofHealth Robotics' technology, both companies decided to form a new jointventure, Health Robotics SEA Ltd., with the purpose of safely, accurately,and cost-effectively compounding I.V. Admixtures in the above mentionedcountries, plus future expansion into Brunei, Thailand, Philippines, Laos,Cambodia, Bangladesh, Sri Lanka, Nepal, Bhutan, Maldives, East Timor, andMyanmar. This joint venture structure will more adequately reflect the needfor a "pay-per-dose" business model by having the partners jointly shareresponsibilities and profits, thus providing more direct involvement andsupport by Health Robotics than traditional "at-arms-length" distributionagreements.
"I'm very pleased to maintain our 100% winning record in everycompetitive I.V. Robotics' purchasing decision in the world since we launchedthe company in mid-2006. Obviously it's an impossible record to forevermaintain, but everyone in our company will certainly enjoy the winning recordwhile it lasts. I have tasked Gaspar DeViedma with the responsibility tomanage Health Robotics' part of this exciting new joint venture in South EastAsia, for which he will be partially relocating from Europe to Asia-Pacificduring a yet to-be-determined period of time. Mr. DeViedma will also overseea future manufacturing expansion of the company in Asia-Pacific to cope withthe sudden growth in the region that Health Robotics has experienced after wesuccessfully changed sales-channel strategies this Summer, including the NTUHdirect intervention in Taiwan, and the soon to be announced Health Robotics'new marketing and operations strategies in China, Australia, and NewZealand", stated Werner Rainer, Health Robotics' CEO.
About Health Robotics:
Health Robotics is the global leading supplier of life-criticalintra-venous medication preparation, compounding, and dispensing Robots,providing healthcare facilities in four continents with robotics technologyand software automation solutions. The world-leading solutions CytoCare[hazardous IVs], i.v.STATION [non-hazardous IVs], i.v.SOFT [workflow engine]and the future development of TPNstation, have and will greatly contribute toease global hospitals' growing pressures to improve patient safety throughthe effective and efficient production of sterile, accurate, andready-to-administer IVs, to eliminate life-threatening drug-exchange errors,to decrease other medication errors and sterility risks, and to work moreefficiently, increase throughput, reduce waste, and contain costs. For moreinformation, please visit http://www.health-robotics.com
About Dr M Group:
Dr M Group is a privately-held conglomerate of business enterprises whosemission is to bring unique high-quality products and services to South EastAsia and to elevate the quality of life standards in the countries itoperates. Dr M Group, a leader in South East Asian Private FinanceInitiatives (PFIs) [initiatives that, in addition to products and services,provide financial support under a public-private partnerships], utilizes itsaccess to capital and its relationships with international organizations suchas the IFC and the World Bank in order to make these high-quality productsand services affordable to the lives of South East Asian populations. Some ifits most recent projects included the safe and efficient optimization ofchemical and hazardous waste disposal services in Malaysia and Vietnam, andthe first-ever Healthcare PFI granted in Malaysia.For additional information, please contact: Health Robotics S.r.l. Gaspar G. DeViedma, General Counsel Europe: +39(346)963-4934 USA: +1(609)980-7976 [email protected] Dr M Group and Health Robotics SEA Ltd. Rejeni Kanthen, Senior Vice President Suite 6.03, Grand Millennium Office Block, Grand Millennium Hotel 160 Jalan Bukit Bintang, 55100 Kuala Lumpur, Malaysia Phone: +60-321648223 [email protected]
SOURCE Health Robotics
